Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Cellegy files NDA for Anogesic; completes enrollment in second phase III trial

June 27, 2001

Pivotal data reported for Xanelim in psoriasis

June 27, 2001

Chemokine antagonists claimed for wide series of conditions in recent patent

June 26, 2001

International Psoriasis Symposium selected by MedImmune to present phase I results for MEDI-507

June 26, 2001

BioMarin files application to conduct human trials with topical Vibriolysin

June 26, 2001

Phase II clinical trial of ISIS-104838 commences in patients with psoriasis

June 22, 2001

Licensing agreement signed for Chugai psoriasis therapeutic

June 20, 2001

Novartis seeks E.U. approval of Elidel atopic dermatitis treatment

June 19, 2001

Patient enrollment complete in safety trial with Miravant topical PhotoPoint drug

June 18, 2001

Tanabe Seiyaku presents small-molecule cell adhesion inhibitors

June 15, 2001

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...